CRISPR Therapeutics AG $CRSP Stock Position Raised by Quantinno Capital Management LP

Key Points

• Quantinno Capital Management increased its CRISPR Therapeutics position by 613.5% in the first quarter, ending with 47,989 shares valued at approximately $2.28 million. Institutional investors collectively own 69.2% of the company.
• Analyst sentiment remains generally positive, with the stock carrying a “Moderate Buy” consensus rating and an average price target of $68.06, compared with a recent opening price of $53.51.
• CRISPR Therapeutics reported a quarterly loss of $0.94 per share on $10.18 million in revenue. Insider Naimish Patel sold shares to cover tax withholding obligations, while the company continues developing CRISPR/Cas9 gene-editing therapies, including its lead CTX001 program.

Quantinno Capital Management LP increased its holdings in shares of CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) by 613.5% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 47,989 shares of the company's stock after acquiring an additional 41,263 shares during the quarter. Quantinno Capital Management LP's holdings in CRISPR Therapeutics were worth $2,283,000 at the end of the most recent quarter.

Other large investors have also recently bought and sold shares of the company. ARK Investment Management LLC grew its holdings in shares of CRISPR Therapeutics by 7.5% during the fourth quarter. ARK Investment Management LLC now owns 10,522,057 shares of the company's stock valued at $551,777,000 after purchasing an additional 735,084 shares during the last quarter. Orbis Allan Gray Ltd lifted its holdings in shares of CRISPR Therapeutics by 19.4% in the 4th quarter. Orbis Allan Gray Ltd now owns 5,950,145 shares of the company's stock worth $312,026,000 after purchasing an additional 968,060 shares during the last quarter. Capital International Investors lifted its holdings in shares of CRISPR Therapeutics by 4.3% in the 4th quarter. Capital International Investors now owns 5,892,745 shares of the company's stock worth $309,016,000 after purchasing an additional 243,487 shares during the last quarter. State Street Corp boosted its position in CRISPR Therapeutics by 35.6% during the 2nd quarter. State Street Corp now owns 3,270,596 shares of the company's stock valued at $159,082,000 after purchasing an additional 859,334 shares during the period. Finally, GSK plc acquired a new position in CRISPR Therapeutics during the 4th quarter valued at approximately $168,890,000. Institutional investors own 69.20% of the company's stock.

Insider Activity at CRISPR Therapeutics

In related news, insider Naimish Patel sold 3,786 shares of the business's stock in a transaction that occurred on Friday, May 29th. The stock was sold at an average price of $55.62, for a total transaction of $210,577.32. Following the sale, the insider owned 19,357 shares of the company's stock, valued at $1,076,636.34. The trade was a 16.36% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 5.20% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on CRSP shares. Morgan Stanley set a $60.00 target price on CRISPR Therapeutics and gave the stock an "equal weight" rating in a research report on Thursday, June 11th. Sanford C. Bernstein upped their price target on shares of CRISPR Therapeutics from $50.00 to $56.00 and gave the stock a "market perform" rating in a research report on Wednesday, May 13th. Evercore reaffirmed an "outperform" rating and issued a $76.00 price objective on shares of CRISPR Therapeutics in a report on Monday, May 11th. Wall Street Zen upgraded shares of CRISPR Therapeutics from a "sell" rating to a "hold" rating in a research report on Saturday. Finally, Citigroup lifted their price objective on shares of CRISPR Therapeutics from $82.00 to $88.00 and gave the company a "buy" rating in a research report on Tuesday, August 4th. One analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, seven have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $68.06.

CRISPR Therapeutics Stock Performance

Shares of CRSP opened at $53.51 on Tuesday. The firm has a 50-day moving average price of $52.36 and a 200 day moving average price of $52.31. The firm has a market capitalization of $5.17 billion, a PE ratio of -11.24 and a beta of 1.74. The company has a quick ratio of 17.85, a current ratio of 17.85 and a debt-to-equity ratio of 0.34. CRISPR Therapeutics AG has a 52-week low of $44.12 and a 52-week high of $78.48.

CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last released its quarterly earnings results on Tuesday, June 30th. The company reported ($0.94) EPS for the quarter. The company had revenue of $10.18 million for the quarter. CRISPR Therapeutics had a negative return on equity of 24.39% and a negative net margin of 3,368.72%. On average, sell-side analysts anticipate that CRISPR Therapeutics AG will post -4.53 earnings per share for the current fiscal year.

CRISPR Therapeutics Profile

CRISPR Therapeutics AG is a biopharmaceutical company specializing in the development of gene-editing therapies based on the CRISPR/Cas9 platform. The company applies its proprietary technology to modify genes in human cells, aiming to create durable treatments for a range of serious diseases. Its research and development efforts focus on both ex vivo and in vivo applications, enabling targeted correction or disruption of disease-causing genes.

Among its lead programs is CTX001, an ex vivo edited cell therapy designed to treat sickle cell disease and transfusion-dependent β-thalassemia in collaboration with Vertex Pharmaceuticals.

Want to see what other hedge funds are holding CRSP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source